The earnings call presented a mix of positive strategic developments and legal victories, particularly regarding the potential launch of YUTREPIA and favorable court rulings. However, this was balanced by financial challenges such as increased operational costs and a larger net loss compared to the previous year.

Company Guidance -

Q2 2025

During the Liquidia Corporation First Quarter 2025 Financial Results and Corporate Update Conference Call, detailed guidance was provided on several key strategic areas in preparation for the potential launch of YUTREPIA, an investigational inhaled dry powder formulation of treprostinil. The company is focusing on developing a best-in-class product profile, emphasizing YUTREPIA's tolerability, titratability, and ease of use. Cohort A of the ASCENT study is fully enrolled with over 50 patients, showing promising interim results, including the ability of PH-ILD patients to titrate to doses 3 times higher than the labeled target dose of nebulized Tyvaso, with positive trends in 6-minute walk distance. The commercial team is ready with 50 sales reps and a companion medical affairs team, all with significant rare disease experience. Additionally, they have prepared a full suite of patient support services and ensured that product availability can commence within 2 to 3 weeks post-approval. The company has also cultivated strong relationships with payers to ensure broad access for patients. Financially, Liquidia reported a revenue of $3.1 million for the quarter ended March 31, 2025, with research and development expenses decreasing by 31% compared to the previous year, attributed to a shift towards commercialization activities. The net loss for the quarter was $38.4 million, or $0.45 per share, compared to a net loss of $30.1 million, or $0.40 per share, in the same period of 2024.

Court Decision Favoring Liquidia

The District Court dismissed United Therapeutics’ cross-claim against Liquidia, clearing legal barriers for YUTREPIA’s potential approval.

ASCENT Study Progress

Cohort A of the ASCENT study is fully enrolled with over 50 patients, showing promising interim data with positive trends in efficacy measures such as 6-minute walk distance.

Strategic Preparations for YUTREPIA Launch

Liquidia is preparing for the launch of YUTREPIA with a focus on product profile, sales force readiness, patient support services, product availability, and payer access.

Reduction in R&D Expenses

Research and development expenses decreased by $3.1 million (31%) compared to the previous year, reflecting a shift towards commercialization.

Liquidia Technologies (LQDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LQDA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.42 / -	-0.37	―	―	―
May 08, 2025	2025 (Q1)	-0.41 / -0.45	-0.54	16.67% (+0.09)	―
Mar 19, 2025	2024 (Q4)	-0.38 / -0.45	-0.43	-4.65% (-0.02)	―
Nov 13, 2024	2024 (Q3)	-0.37 / -0.30	-0.24	-25.00% (-0.06)	―
Aug 07, 2024	2024 (Q2)	-0.34 / -0.37	-0.36	-2.78% (-0.01)	―
May 13, 2024	2024 (Q1)	-0.32 / -0.54	-0.18	-200.00% (-0.36)	―
Mar 13, 2024	2023 (Q4)	-0.24 / -0.43	-0.08	-437.50% (-0.35)	―
Nov 07, 2023	2023 (Q3)	-0.21 / -0.24	-0.14	-71.43% (-0.10)	―
Aug 10, 2023	2023 (Q2)	-0.16 / -0.36	-0.15	-140.00% (-0.21)	―
May 04, 2023	2023 (Q1)	-0.16 / -0.18	-0.3	40.00% (+0.12)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LQDA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$15.53	$15.35	-1.16%
Mar 19, 2025	$14.74	$14.92	+1.22%
Nov 13, 2024	$10.63	$10.27	-3.39%
Aug 07, 2024	$11.06	$10.68	-3.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Liquidia Technologies (LQDA) report earnings?

Liquidia Technologies (LQDA) is schdueled to report earning on Aug 12, 2025, TBA (Confirmed).

What is Liquidia Technologies (LQDA) earnings time?

Liquidia Technologies (LQDA) earnings time is at Aug 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LQDA EPS forecast?

LQDA EPS forecast for the fiscal quarter 2025 (Q2) is -0.43.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing